Chen Sixia, Yang Dong, Liao Xueyin, Lu Ying, Yu Bin, Xu Meng, Bin Ying, Zhou Pingting, Yang Zhendong, Liu Kang, Wang Rensheng, Zhao Tingting, Kang Min
Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Guangxi Tumor Radiation Therapy Clinical Medical Research Center, Nanning, China.
Front Oncol. 2022 Feb 11;11:693199. doi: 10.3389/fonc.2021.693199. eCollection 2021.
This study aimed to explore factors associated with recurrence and metastasis after intensity-modulated radiotherapy (IMRT) in patients with nasopharyngeal carcinoma (NPC) and provide evidence for NPC treatment.
We retrospectively analysed the treatment dose and survival outcomes of 645 patients with nasopharyngeal carcinoma without distant metastases treated with IMRT for the first time at three treatment centres in the Guangxi Zhuang Autonomous Region, China, between January 2009 and December 2012.
There were 9.3% of patients (60/645) had recurrence and 17.5% (113/645) had distant metastasis 5 years after treatment. The 1-year, 3-year and 5-year local recurrence rates were 0.9%, 6.5% and 9.0% respectively. And the 1-year, 3-year and 5-year distant metastasis rates were 3.4%, 10% and 17.2%, respectively. In the 60 patients with recurrence, the in-field, marginal-field, and out-field recurrence rates were 93.3% (56/60), 5.0% (3/60) and 1.7% (1/60), respectively. Recurrence failures occurring within the first three years after treatment accounted for 81.7% (49/60). In the 113 patients with metastasis, the size of the cervical lymph node, the presence of lower cervical lymph node metastasis, the residual cervical lymph node size and the time of residual cervical lymph node complete response (CR) were independent prognostic factors for DMFS (0.05).
Most recurrences occured in the first three years after IMRT. In-field recurrence was the most common pattern for loco-regional failure of NPC treatment. The risk of distant metastasis was positively correlated with higher N stage, lower neck nodal metastasis, larger size of cervical lymph nodes, and longer time to response for residual NPC in cervical adenopathy.
本研究旨在探讨鼻咽癌(NPC)患者调强放射治疗(IMRT)后复发和转移的相关因素,为鼻咽癌治疗提供依据。
我们回顾性分析了2009年1月至2012年12月期间在中国广西壮族自治区三个治疗中心首次接受IMRT治疗的645例无远处转移的鼻咽癌患者的治疗剂量和生存结果。
治疗后5年,9.3%(60/645)的患者出现复发,17.5%(113/645)的患者出现远处转移。1年、3年和5年的局部复发率分别为0.9%、6.5%和9.0%。1年、3年和5年的远处转移率分别为3.4%、10%和17.2%。在60例复发患者中,野内、边缘野和野外复发率分别为93.3%(56/60)、5.0%(3/60)和1.7%(1/60)。治疗后前三年发生的复发失败占81.7%(49/60)。在113例转移患者中,颈部淋巴结大小、下颈部淋巴结转移情况、残留颈部淋巴结大小以及残留颈部淋巴结完全缓解(CR)时间是远处转移无进展生存期(DMFS)的独立预后因素(P<0.05)。
大多数复发发生在IMRT后的前三年。野内复发是NPC治疗局部区域失败最常见的模式。远处转移风险与较高的N分期、下颈部淋巴结转移、颈部淋巴结较大尺寸以及颈部淋巴结病残留NPC的缓解时间较长呈正相关。